Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. OncologyPRO
  2. Meeting resources
  3. ESMO Congress

Mini Oral session: GI, upper digestive

53MO - Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116)

Date

10 Sep 2022

Session

Mini Oral session: GI, upper digestive

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Arndt Vogel

Citation

Annals of Oncology (2022) 33 (suppl_7): S19-S26. 10.1016/annonc/annonc1036

Authors

A. Vogel1, P. Wenzel2, G. Folprecht3, P. Schütt4, H. Wege5, A. Kretzschmar6, L. Jacobasch7, N. Ziegenhagen8, S. Boeck9, S. Kanzler10, J. Mohm11, S. Belle12, D. Pink13, T.O. Götze14, E. Goekkurt15, U. Graeven16, M. Schaaf17, M. Kirstein18, A. Saborowski19

Author affiliations

  • 1 Department For Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 30625 - Hannover/DE
  • 2 Department Of Internal Medicine Ii, Technical University Of Munich, School Of Medicine, University Hospital rechts der Isar, 81675 - Munich/DE
  • 3 Medical Clinic And Polyclinic I, Universitaetsklinikum Carl Gustav Carus, 01307 - Dresden/DE
  • 4 Joint Practice For Oncology, Oncodoc GmbH, Gütersloh/DE
  • 5 Department Of Internal Medicine, Gastroenterology And Hepatology, University Medical Center Hamburg-Eppendorf, 20246 - Hamburg/DE
  • 6 Internal Oncology And Hematology, Medical Care Center MVZ Mitte, 04129 - Leipzig/DE
  • 7 Bag, Gemeinschaftspraxis BAG- Joint Practice for Oncology, 01307 - Dresden/DE
  • 8 Department Of Oncology And Palliative Care, HELIOS Hospital Berlin-Buch, Berlin/DE
  • 9 Department Of Internal Medicine Iii And Comprehensive Cancer Center, Klinikum Grosshadern, LMU - Ludwig Maximilians University of Munich, 80539 - Munich/DE
  • 10 Medical Clinic Ii, Leopoldina Hospital, 97422 - Schweinfurt/DE
  • 11 Practice Hematology And Oncology, Onkopraxis, 01307 - Dresden/DE
  • 12 Department Of Medicine Ii, Medical Faculty Mannheim, University of Heidelberg, 68167 - Mannheim/DE
  • 13 Department Of Oncology And Palliative Care, Helios Clinic Bad Saarow, Bad Saarow, Germany And Internal Medicine C, University Medicine Greifswald, 15526 - Bad Saarow/DE
  • 14 Institute Of Clinical Cancer Research - Northwest Hospital Frankfurt, University Cancer Center Frankfurt- Marburg, 60488 - Frankfurt am Main/DE
  • 15 Practice Eppendorf Hope, Hematological Oncology, 20249 - Hamburg/DE
  • 16 Department Of Hematology, Oncology And Gastroenterology, Kliniken Maria Hilf - St. Franziskus Hospital, 41063 - Mönchengladbach/DE
  • 17 Institute Of Clinical Cancer Research Ikf, Uct-university Cancer Center, KHNW - Krankenhaus Nordwest GmbH, 60488 - Frankfurt am Main/DE
  • 18 1st Department Of Medicine, University Medical Center Schleswig-Holstein, Campus Luebeck, 23562 - Luebeck/DE
  • 19 Department For Gastroenterology, Hepatology And Endocrinology, Hannover Medical School, 30625 - Hannover/DE
More

Resources

Login to access the resources on OncologyPRO.

Login

Abstract 53MO

Background

Therapeutic options in pre-treated advanced biliary tract cancer (BTC) are limited. Although the ABC-06 trial demonstrated clinical benefit for mFOLFOX, there is an unmet need for more effective 2nd line therapies. The aim of this study was to evaluate the efficacy of pegylated liposomal irinotecan formulation (nal-IRI)/5-FU/leucovorin (LV) compared to 5-FU/LV in 2nd line BTC.

Methods

NALIRICC is a prospective, randomized, two-sided, phase II study. Pts > 18 years, with ECOG PS 0/1, histologically confirmed metastatic BTC and progression on 1st line Gemcitabine-based therapy were eligible. Trial interventions were Arm A nal-IRI (80 mg/m2) plus 5-FU (2400 mg/m2)/LV (400 mg/m2), q2w or Arm B 5-FU/LV, q2w. Pts were stratified according to primary tumor site, and response was evaluated per RECIST v1.1, every 6 weeks. Primary endpoint (EP) was progression-free survival (PFS). Secondary EPs were overall survival (OS), overall response rates (ORR), safety and QoL (EORTC QLQ C30). This study was designed to improve median PFS from 1.5 months (P0) to 3 months (P1; HR 0.5) with 2-sided α of 0.05, power of 90.3%; 99 pts required in total.

Results

In total 100 pts were randomized in 17 German centers (49 pts: nal-IRI/5-FU/LV arm/ 51 pts: 5-FU/LV arm). 64/19/17 pts had intra-/extrahepatic/gallbladder cancers. Pt characteristics were well balanced between the two arms. Trial results see the table. Most common grade ≥3 Adverse Events in nal-IRI/5-FU/LV group were decreased neutrophil counts (16.6%), diarrhea (14.6%), and nausea (8.3%). 27.5% of patients in the 5-FU/LV groups received irinotecan-based therapies post-progression. QoL was similar between both arms. Table: 53MO

NALIRICC-Trial results, median follow-up of 5,9 months

Treament arm ORR [%] mOS [months] mPFS [months] AEs ≥ 3 in % of pts
Arm A, Nal-IRI and 5-FU/LV, n=49 14.3 6.9 2.76 70.8
Arm B, 5-FU/LV, n=51 3.9 8.21 2.3 50

Conclusions

The NALIRICC-trial did not meet its primary EP. The addition of nal-IRI to 5-FU/LV did not improve PFS or OS compared to 5-FU/LV alone and was associated with higher toxicity. 5FU/LV may be considered as a reasonable alternative in 2nd line advanced BTC.

Clinical trial identification

NCT03043547.

Editorial acknowledgement

Legal entity responsible for the study

AIO-Studien-gGmbH.

Funding

AIO-Studien-gGmbH supported by Servier.

Disclosure

A. Vogel: Financial Interests, Personal, Invited Speaker: Roche, BMS, MSD, Novartis, Eisai, Ipsen, Incyte, PierreFabre, Lilly, Imaging Equipment Ltd (AAA), Roche, MSD, Beigene, Jiangsu Hengrui Medicines.; Financial Interests, Personal, Advisory Board: Roche, Bayer, BMS, MSD, Eisai, Ipsen, Incyte, PierreFabre, Lilly, AstraZeneca, Boston Scientific, Sirtex, Daiichi-Sankyo. G. Folprecht: Financial Interests, Personal, Invited Speaker: Roche / Genentech, Falk Foundation, Lilly; Financial Interests, Personal, Advisory Board: Sanofi-Aventis, Merck, BMS, MSD, Servier, Pierre Fabre, Roche / Genentech, Bayer, Exact Sciences. A. Kretzschmar: Financial Interests, Personal, Advisory Role: Servier, Roche, BMS, MSD, Merck, Sanofi. N. Ziegenhagen: Financial Interests, Institutional, Sponsor/Funding, Clinical Trial: Pfizer, Boehringer Ingelheim, MSD Sharp & Dohme GmbH, Astellas Pharma, Amgen; Non-Financial Interests, Institutional, Member, Membership: ESMO. S. Boeck: Financial Interests, Personal, Project Lead: Incyte; Financial Interests, Institutional, Sponsor/Funding, Clinical Trial: Servier. D. Pink: Financial Interests, Institutional, Invited Speaker: Blueprint, PharmaMar, BMS, EUSA-Pharma, PharmaMar, Lilly, Roche; Financial Interests, Institutional, Advisory Board: Roche, PharmaMar, Boehringer Ingelheim; Financial Interests, Institutional, Other, scientific lead of a trial with funding from Novartis: Novartis; Non-Financial Interests, Member: ASCO, Deutsche Krebsgesellschaft - German Cancer Society (DKG), Connective Tissue Oncology Society (CTOS), Deutsche Sarkomstiftung (DSS). T.O. Götze: Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Bayer, BMS, Daiichi Sankyo, Foundation Medicine, Lilly, MCI, MSD Sharp Dohme, Novartis, Roche, Sanofi, Aventis, Servier; Financial Interests, Personal, Project Lead: Lilly, AstraZeneca, Incyte, DGF German Research Foundation, GBA Gemeinsamer Bundesausschuss, Deutsche Krebshilfe. E. Goekkurt: Financial Interests, Institutional, Advisory Board: BMS, Daiichi Sankyo, MSD; Financial Interests, Institutional, Principal Investigator, local PI: AstraZeneca, BMS, Daiichi Sankyo, MSD, Novartis. U. Graeven: Financial Interests, Personal, Stocks/Shares: Biontech; Financial Interests, Personal, Advisory Role, Honoraria: Boehringer Ingelheim, Amgen, AstraZeneca, BMS, MSD Oncology, Sanofi Aventis, Fujifilm, Novartis; Financial Interests, Personal, Other, Travelexpenses: Merck KGaA, Amgen, Boehringer Ingelheim, GSK. A. Saborowski: Financial Interests, Personal, Advisory Role: Roche, BMS, Falk Foundation, Servier. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.